Assay development for hit identification MCQs With Answer

This set of MCQs is tailored for M.Pharm students focusing on assay development for hit identification, a pivotal phase in early drug discovery. It covers practical and theoretical aspects such as assay selection (biochemical vs cell-based), optimization parameters (signal window, Z’-factor), readout technologies, interference liabilities (PAINS, autofluorescence, aggregation), controls, counterscreens and orthogonal confirmation. Questions emphasize robustness, miniaturization, DMSO tolerance, data quality metrics and hit validation workflows to prepare you for designing, evaluating and interpreting high-throughput and cell-based screening campaigns. Answers are provided for self-evaluation to guide study.

Q1. What is the primary objective when developing an assay for hit identification in high-throughput screening (HTS)?

• Create a robust, reproducible and scalable assay with an adequate signal window and low variability suitable for HTS
• Maximize the absolute signal intensity regardless of variability
• Design an assay that gives the highest number of active compounds
• Develop the most complex cellular assay possible to mimic in vivo conditions

Correct Answer: Create a robust, reproducible and scalable assay with an adequate signal window and low variability suitable for HTS

Q2. Which expression correctly represents the widely used Z’-factor for assay quality?

• Z’ = 1 – (3*(SD_positive + SD_negative) / |mean_positive – mean_negative|)
• Z’ = (mean_positive – mean_negative) / (SD_positive + SD_negative)
• Z’ = (mean_positive + mean_negative) / (SD_positive – SD_negative)
• Z’ = (SD_positive + SD_negative) / (mean_positive – mean_negative)

Correct Answer: Z’ = 1 – (3*(SD_positive + SD_negative) / |mean_positive – mean_negative|)

Q3. For routine HTS, which Z’-factor value is generally considered acceptable to indicate a robust assay?

• Z’ > 0.5
• Z’ between 0 and 0.2
• Z’ < 0
• Z’ exactly equal to 1

Correct Answer: Z’ > 0.5

Q4. Which statement best distinguishes a biochemical assay from a cell-based assay during hit identification?

• A biochemical assay measures direct target activity in a defined system, while a cell-based assay measures compound effects within cellular context including permeability and pathway interactions
• A biochemical assay always uses live cells and measures phenotypic changes, cell-based assays use purified protein
• Biochemical assays are always less specific than cell-based assays
• Cell-based assays have no risk of interference and are therefore preferred for primary HTS

Correct Answer: A biochemical assay measures direct target activity in a defined system, while a cell-based assay measures compound effects within cellular context including permeability and pathway interactions

Q5. What is the main purpose of including a counterscreen in a hit identification workflow?

• To identify and eliminate compounds that interfere with the assay detection method or act through off-target artifacts
• To increase the primary assay throughput
• To measure pharmacokinetics in vivo
• To replace orthogonal assays in hit validation

Correct Answer: To identify and eliminate compounds that interfere with the assay detection method or act through off-target artifacts

Q6. What is a commonly acceptable DMSO concentration in HTS assay buffers that most assays tolerate without significant interference?

• Up to 1% (v/v) DMSO without significant interference
• Greater than 10% (v/v) DMSO is standard
• DMSO must be totally excluded (0%) from all screening assays
• Exactly 5% (v/v) DMSO is required for all enzyme assays

Correct Answer: Up to 1% (v/v) DMSO without significant interference

Q7. What does the acronym PAINS denote in the context of screening libraries?

• Pan-Assay Interference Compounds that frequently produce false positives across diverse assays
• Potential Active Ionizable Nucleophilic Substances used as cofactors
• Protein-Associated Inhibitory Non-specifics that indicate true target binding
• Pure Assay-Independent Natural Substances preferred for screening

Correct Answer: Pan-Assay Interference Compounds that frequently produce false positives across diverse assays

Q8. Which readout modality typically gives the highest sensitivity and lowest background for many HTS formats?

• Luminescence-based assays
• Absorbance-based assays
• Standard intensity fluorescence without time-gating
• Light microscopy imaging without signal amplification

Correct Answer: Luminescence-based assays

Q9. What is the principal advantage of time-resolved FRET (TR-FRET) compared with steady-state fluorescence in screening?

• TR-FRET reduces interference from short-lifetime autofluorescence by using time-delayed measurements, improving signal-to-noise
• TR-FRET eliminates the need for fluorescent labels altogether
• TR-FRET always produces larger absolute signals than luminescence
• TR-FRET requires longer incubation times and cannot be used in HTS

Correct Answer: TR-FRET reduces interference from short-lifetime autofluorescence by using time-delayed measurements, improving signal-to-noise

Q10. How does the Z’-factor differ conceptually from signal-to-noise (S/N) when assessing assay quality?

• Z’ accounts for both dynamic range (signal window) and variability of controls, whereas S/N only considers signal amplitude relative to background noise
• Z’ measures absolute signal intensity and ignores variability, while S/N measures reproducibility
• Z’ is equivalent to S/N for all assays
• S/N includes control variability explicitly while Z’ does not

Correct Answer: Z’ accounts for both dynamic range (signal window) and variability of controls, whereas S/N only considers signal amplitude relative to background noise

Q11. Which is the best description of an orthogonal assay in hit validation?

• An assay that confirms hits using a different detection method or biology to rule out assay-specific artifacts
• An identical repeat of the primary screen to increase confidence
• A computational docking study used instead of experimental confirmation
• A counterscreen that measures unrelated off-target activity

Correct Answer: An assay that confirms hits using a different detection method or biology to rule out assay-specific artifacts

Q12. What is a major advantage of miniaturizing assays (e.g., moving from 96- to 384- or 1536-well format)?

• Reduced reagent consumption and cost per data point with increased throughput, while maintaining acceptable assay quality
• Increased reagent consumption to improve signal intensity
• Guaranteed elimination of all assay artifacts
• Requirement for manual pipetting to improve accuracy

Correct Answer: Reduced reagent consumption and cost per data point with increased throughput, while maintaining acceptable assay quality

Q13. In assay development, what role does a positive control typically play?

Correct Answer:

Q14. Which mechanism commonly causes false-positive readouts in fluorescence-based biochemical assays?

• Compound fluorescence or quenching (autofluorescence) and compound aggregation that affects the signal
• Low DMSO concentrations improving assay signal
• Excessive plate washing leading to increased signal
• Using luminescent substrates exclusively

Correct Answer: Compound fluorescence or quenching (autofluorescence) and compound aggregation that affects the signal

Q15. How does an IC50 value differ from a Ki when characterizing an inhibitor?

• IC50 is assay- and condition-dependent (depends on substrate concentration), whereas Ki is an intrinsic affinity constant independent of substrate concentration
• IC50 is intrinsic and independent of assay conditions, while Ki varies with substrate concentration
• IC50 always equals Ki for competitive inhibitors
• Ki measures toxicity while IC50 measures solubility

Correct Answer: IC50 is assay- and condition-dependent (depends on substrate concentration), whereas Ki is an intrinsic affinity constant independent of substrate concentration

Q16. Which experimental modification is commonly used as a simple counterscreen to detect aggregation-based inhibitors?

• Addition of a low concentration of non-ionic detergent (e.g., 0.01–0.1% Tween-20 or Triton X-100) to disrupt colloidal aggregates
• Increasing DMSO to 10% to precipitate aggregated compounds
• Removing all salts from assay buffer to promote aggregation
• Lowering temperature to near-freezing to stabilize aggregates

Correct Answer: Addition of a low concentration of non-ionic detergent (e.g., 0.01–0.1% Tween-20 or Triton X-100) to disrupt colloidal aggregates

Q17. Which microplate format frequently represents the best compromise between throughput, reagent use and ease of handling for many academic and industrial HTS labs?

• 384-well plates
• 6-well plates
• 24-well plates
• 1536-well plates are always preferable regardless of equipment

Correct Answer: 384-well plates

Q18. How is the signal window commonly defined in assay development?

• The difference between the mean responses of positive and negative controls (mean_positive − mean_negative)
• The sum of standard deviations of positive and negative controls
• The ratio of background to signal means
• The percentage of wells showing activity in the primary screen

Correct Answer: The difference between the mean responses of positive and negative controls (mean_positive − mean_negative)

Q19. When is a kinetic (real-time) assay preferred over an endpoint assay during hit identification?

• When reaction rates, transient intermediates or time-dependent inhibition must be measured and time course information guides hit selection
• Always; endpoint assays are obsolete and should not be used
• Only when using absorbance readouts regardless of biology
• When assay throughput must be maximized at the expense of mechanistic insight

Correct Answer: When reaction rates, transient intermediates or time-dependent inhibition must be measured and time course information guides hit selection

Q20. Which sequence best represents a typical hit validation workflow after a primary HTS hit list is generated?

• Retest primary hits → counterscreens to remove assay artifacts → orthogonal assays for confirmation → dose-response characterization → mechanism and selectivity studies
• Mechanism studies → primary HTS → orthogonal assays → counterscreens
• Direct in vivo testing → orthogonal assays → counterscreens → retest
• Ignore counterscreens and proceed directly to medicinal chemistry

Correct Answer: Retest primary hits → counterscreens to remove assay artifacts → orthogonal assays for confirmation → dose-response characterization → mechanism and selectivity studies

Download